MY193968A - Use of plinabulin in combination with immune checkpoint inhibitors - Google Patents
Use of plinabulin in combination with immune checkpoint inhibitorsInfo
- Publication number
- MY193968A MY193968A MYPI2017702826A MYPI2017702826A MY193968A MY 193968 A MY193968 A MY 193968A MY PI2017702826 A MYPI2017702826 A MY PI2017702826A MY PI2017702826 A MYPI2017702826 A MY PI2017702826A MY 193968 A MY193968 A MY 193968A
- Authority
- MY
- Malaysia
- Prior art keywords
- plinabulin
- immune checkpoint
- combination
- checkpoint inhibitors
- treating cancer
- Prior art date
Links
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 title abstract 3
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 title abstract 3
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 title abstract 3
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 title abstract 3
- UNRCMCRRFYFGFX-TYPNBTCFSA-N plinabulin Chemical compound N1C=NC(\C=C/2C(NC(=C\C=3C=CC=CC=3)/C(=O)N\2)=O)=C1C(C)(C)C UNRCMCRRFYFGFX-TYPNBTCFSA-N 0.000 title abstract 3
- 229950011498 plinabulin Drugs 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562115468P | 2015-02-12 | 2015-02-12 | |
| US201562255259P | 2015-11-13 | 2015-11-13 | |
| PCT/US2016/017602 WO2016130839A1 (en) | 2015-02-12 | 2016-02-11 | Use of plinabulin in combination with immune checkpoint inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY193968A true MY193968A (en) | 2022-11-03 |
Family
ID=56615698
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2017702826A MY193968A (en) | 2015-02-12 | 2016-02-11 | Use of plinabulin in combination with immune checkpoint inhibitors |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20180028531A1 (enExample) |
| EP (1) | EP3256130A4 (enExample) |
| JP (4) | JP7243021B2 (enExample) |
| KR (2) | KR20170117113A (enExample) |
| CN (2) | CN107427510A (enExample) |
| AU (3) | AU2016219204B2 (enExample) |
| CA (1) | CA2975729A1 (enExample) |
| CL (1) | CL2017002050A1 (enExample) |
| HK (1) | HK1247816A1 (enExample) |
| IL (2) | IL286282B2 (enExample) |
| MX (2) | MX394865B (enExample) |
| MY (1) | MY193968A (enExample) |
| NZ (1) | NZ734256A (enExample) |
| RU (1) | RU2723021C2 (enExample) |
| SG (1) | SG11201706281YA (enExample) |
| WO (1) | WO2016130839A1 (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101495951B1 (ko) | 2009-03-30 | 2015-02-25 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 리포솜 조성물 |
| CA2974651A1 (en) | 2014-01-24 | 2015-07-30 | Children's Hospital Of Eastern Ontario Research Institute Inc. | Smc combination therapy for the treatment of cancer |
| RU2728796C2 (ru) | 2015-03-06 | 2020-07-31 | Бейондспринг Фармасьютикалс, Инк. | Способ лечения опухоли головного мозга |
| SG10202008673WA (en) | 2015-03-06 | 2020-10-29 | Beyondspring Pharmaceuticals Inc | Method of treating cancer associated with a ras mutation |
| HK1252026A1 (zh) * | 2015-06-11 | 2019-05-10 | Bionomics Limited | 药物组合及其应用 |
| CN109516981B (zh) | 2015-07-13 | 2019-10-22 | 大连万春布林医药有限公司 | 普那布林组合物 |
| US10912748B2 (en) | 2016-02-08 | 2021-02-09 | Beyondspring Pharmaceuticals, Inc. | Compositions containing tucaresol or its analogs |
| EP3449921B1 (en) | 2016-04-28 | 2023-05-31 | Eisai R&D Management Co., Ltd. | Eribulin for inhibiting tumor growth |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| KR20240091084A (ko) | 2016-06-06 | 2024-06-21 | 비욘드스프링 파마수티컬스, 인코포레이티드. | 호중구감소증을 줄이는 조성물 및 방법 |
| CN109906088A (zh) | 2016-08-26 | 2019-06-18 | 奥野哲治 | 微血管血流减少剂及其应用 |
| WO2018071792A1 (en) * | 2016-10-14 | 2018-04-19 | Merck Sharp & Dohme Corp. | Combination of a pd-1 antagonist and eribulin for treating urothelial cancer |
| JP2020503363A (ja) | 2017-01-06 | 2020-01-30 | ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド | チューブリン結合化合物およびその治療的使用 |
| IL268305B2 (en) | 2017-02-01 | 2024-08-01 | Beyondspring Pharmaceuticals Inc | Plinabulin in combination with one or more g-csf drug for use in the therapeutic treatment of docetaxel-induced |
| BR112019018880A2 (pt) * | 2017-03-13 | 2020-04-14 | Beyondspring Pharmaceuticals Inc | composições de plinabulina e seu uso |
| WO2019022501A1 (en) * | 2017-07-26 | 2019-01-31 | Chong Kun Dang Pharmaceutical Corp. | COMPOSITION FOR THE PREVENTION OR TREATMENT OF CANCER COMPRISING A VASCULAR DISRUPTION AGENT AND AN IMMUNE CONTROL POINT INHIBITOR |
| CA3074876A1 (en) * | 2017-09-08 | 2019-03-14 | University Health Network | Combination therapies for inhibition of polo-like kinase 4 |
| CN109498627B (zh) * | 2017-09-15 | 2021-06-04 | 深圳华大海洋科技有限公司 | 一种治疗肿瘤的药物组合物及其应用 |
| US11786523B2 (en) | 2018-01-24 | 2023-10-17 | Beyondspring Pharmaceuticals, Inc. | Composition and method for reducing thrombocytopenia |
| JP7500438B2 (ja) * | 2018-06-01 | 2024-06-17 | ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド | Ｅｇｆｒ変異に関連する癌の治療組成物及び治療方法 |
| CN108524442B (zh) * | 2018-06-05 | 2022-01-28 | 深圳海王医药科技研究院有限公司 | 一种抗肿瘤药物的注射剂及其制备方法 |
| US20210177952A1 (en) * | 2018-08-16 | 2021-06-17 | Beyondspring Pharmaceuticals, Inc. | Method and composition for stimulating immune response |
| US20210369787A1 (en) * | 2018-11-01 | 2021-12-02 | North Carolina State University | Adipocyte mediated delivery of anticancer therapeutics |
| CN110265095A (zh) * | 2019-05-22 | 2019-09-20 | 首都医科大学附属北京佑安医院 | 用于hcc复发及rfs的预测模型和诺模图的构建方法及应用 |
| US12036204B2 (en) | 2019-07-26 | 2024-07-16 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition for treating tumor |
| CN112778155B (zh) * | 2019-11-11 | 2023-08-11 | 大连万春布林医药有限公司 | 妥卡雷琐衍生物及其用途 |
| US20230181605A1 (en) * | 2020-05-04 | 2023-06-15 | Beyondspring Pharmaceuticals, Inc. | Triple combination therapy for enhancing cancer cell killing in cancers with low immunogenicity |
| WO2022133492A1 (en) * | 2020-12-18 | 2022-06-23 | Beyondspring Pharmaceuticals, Inc. | Compositions and methods for generating anti-tumor immune response |
| JP2024513505A (ja) | 2021-04-09 | 2024-03-25 | ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド | 腫瘍を治療するための組成物及び方法 |
| CN113456643B (zh) * | 2021-08-11 | 2022-04-01 | 遵义医科大学 | 一种含普那布林的药物组合及其应用 |
| CN117860672A (zh) | 2022-10-11 | 2024-04-12 | 大连万春布林医药有限公司 | 一种普那布林胶束组合物及其制备方法 |
| CN121127241A (zh) * | 2023-03-10 | 2025-12-12 | 万春药业公司 | 肿瘤联合治疗及使用方法 |
| WO2025006507A1 (en) * | 2023-06-27 | 2025-01-02 | Beyondspring Pharmaceuticals, Inc. | Oncology combination therapy and methods of use |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA05001217A (es) * | 2002-08-02 | 2005-05-16 | Nereus Pharmaceuticals Inc | Deshidrofenilahistinas y sus analogos y la sintesis de deshidrofenilahistinas y sus analogos. |
| CA2553630A1 (en) * | 2004-02-04 | 2005-08-25 | Nereus Pharmaceuticals, Inc. | Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof |
| CN109485727A (zh) * | 2005-05-09 | 2019-03-19 | 小野药品工业株式会社 | 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法 |
| US8569262B2 (en) * | 2007-11-02 | 2013-10-29 | Momenta Pharmaceuticals, Inc. | Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization |
| EP2227296B1 (en) * | 2008-01-08 | 2015-11-25 | Bristol-Myers Squibb Company | Combination of anti-ctla4 antibody with tubulin modulating agents for the treatment of proliferative diseases |
| CN102256944A (zh) * | 2008-10-17 | 2011-11-23 | 埃克塞利希斯股份有限公司 | 鞘氨醇-1-磷酸受体拮抗剂 |
| JP5855568B2 (ja) * | 2009-09-15 | 2016-02-09 | セルリアン・ファーマ・インコーポレイテッド | 癌の治療法 |
| WO2011146382A1 (en) * | 2010-05-17 | 2011-11-24 | Bristol-Myers Squibb Company | Improved immunotherapeutic dosing regimens and combinations thereof |
| WO2012035436A1 (en) * | 2010-09-15 | 2012-03-22 | Tokyo University Of Pharmacy And Life Sciences | Plinabulin prodrug analogs and therapeutic uses thereof |
| WO2013090552A1 (en) * | 2011-12-13 | 2013-06-20 | Yale University | Compositions and methods for reducing ctl exhaustion |
| AU2013308595C1 (en) * | 2012-08-30 | 2019-01-17 | Amgen Inc. | A method for treating melanoma using a herpes simplex virus and an immune checkpoint inhibitor |
| WO2014066834A1 (en) * | 2012-10-26 | 2014-05-01 | The University Of Chicago | Synergistic combination of immunologic inhibitors for the treatment of cancer |
| SG11201505896YA (en) * | 2013-02-20 | 2015-09-29 | Novartis Ag | Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor |
| US11083743B2 (en) * | 2013-02-21 | 2021-08-10 | Michele Maio | DNA hypomethylating agents for cancer therapy |
| US10260038B2 (en) * | 2013-05-10 | 2019-04-16 | Whitehead Institute For Biomedical Research | Protein modification of living cells using sortase |
| KR20160013049A (ko) * | 2013-06-03 | 2016-02-03 | 노파르티스 아게 | 항-pd-l1 항체 및 mek 억제제 및/또는 braf 억제제의 조합물 |
| WO2015051543A1 (en) * | 2013-10-11 | 2015-04-16 | Dalian Wanchun Biotechnology Co., Ltd. | Cancer treatment with combination of plinabulin and taxane |
| US10912748B2 (en) * | 2016-02-08 | 2021-02-09 | Beyondspring Pharmaceuticals, Inc. | Compositions containing tucaresol or its analogs |
-
2016
- 2016-02-11 KR KR1020177025140A patent/KR20170117113A/ko not_active Ceased
- 2016-02-11 EP EP16749903.7A patent/EP3256130A4/en active Pending
- 2016-02-11 AU AU2016219204A patent/AU2016219204B2/en active Active
- 2016-02-11 CN CN201680015268.XA patent/CN107427510A/zh active Pending
- 2016-02-11 HK HK18107194.9A patent/HK1247816A1/zh unknown
- 2016-02-11 WO PCT/US2016/017602 patent/WO2016130839A1/en not_active Ceased
- 2016-02-11 US US15/550,350 patent/US20180028531A1/en not_active Abandoned
- 2016-02-11 MY MYPI2017702826A patent/MY193968A/en unknown
- 2016-02-11 CN CN202311274843.6A patent/CN117100753A/zh active Pending
- 2016-02-11 JP JP2017560890A patent/JP7243021B2/ja active Active
- 2016-02-11 KR KR1020247022015A patent/KR20240110996A/ko active Pending
- 2016-02-11 NZ NZ734256A patent/NZ734256A/en unknown
- 2016-02-11 MX MX2017010338A patent/MX394865B/es unknown
- 2016-02-11 SG SG11201706281YA patent/SG11201706281YA/en unknown
- 2016-02-11 IL IL286282A patent/IL286282B2/en unknown
- 2016-02-11 RU RU2017127966A patent/RU2723021C2/ru active
- 2016-02-11 CA CA2975729A patent/CA2975729A1/en active Pending
-
2017
- 2017-08-01 IL IL253784A patent/IL253784B/en unknown
- 2017-08-10 MX MX2022007472A patent/MX2022007472A/es unknown
- 2017-08-10 CL CL2017002050A patent/CL2017002050A1/es unknown
-
2021
- 2021-01-07 JP JP2021001505A patent/JP7157181B2/ja active Active
- 2021-04-21 AU AU2021202416A patent/AU2021202416B2/en active Active
-
2022
- 2022-11-01 JP JP2022175377A patent/JP7564172B2/ja active Active
-
2024
- 2024-02-02 AU AU2024200672A patent/AU2024200672A1/en active Pending
- 2024-09-26 JP JP2024167302A patent/JP2024174070A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022007472A (es) | Uso de plinabulina en combinacion con inhibidores de punto de control inmunitario. | |
| IL272877A (en) | SHP2 inhibitory compositions and methods for cancer treatment | |
| ZA202208792B (en) | Methods of treating and preventing graft versus host disease | |
| HUE053763T2 (hu) | Immunellenõrzésipont-gátlók véreredetû rákok kezelésében történõ alkalmazásra | |
| BR112015011756A2 (pt) | inibidores da glutamase e métodos de uso | |
| MA40437A (fr) | Méthodes de traitement du cancer faisant appel à des inhibiteurs de tigit et à des agents anticancéreux | |
| PH12016500511A1 (en) | Selective grp94 inhibitors and uses thereof | |
| PH12019501763A1 (en) | Method of reducing neutropenia | |
| EA201992251A1 (ru) | Противораковые вакцины и способы лечения с их применением | |
| SG10201808940WA (en) | Nox inhibitor and nfкb inhibitor containing methoxyflavone | |
| CL2016000326A1 (es) | Composiciones y método para tratar condiciones asociadas con el complemento | |
| MX377593B (es) | Composiciones para usar en el tratamiento de cáncer renal. | |
| MX2018000715A (es) | Metodos para tratar cancer usando apilimod. | |
| DOP2017000111A (es) | Inhibidor de cinasa aurora a | |
| IL271326A (en) | Compositions and methods for enhancing cancer radiotherapy | |
| BR112016017112A2 (pt) | Composições de apilimod e métodos de uso das mesmas | |
| IL251761B (en) | A combination of alpha thymosin and a pd-1 inhibitor is beneficial in the treatment of cancer | |
| MX2017006026A (es) | Apilimod para uso en el tratamiento de cancer colorrectal. | |
| PH12017501022B1 (en) | Compositions comprising 15-hepe and methods of treating or preventing fibrosis using same | |
| MX2020002585A (es) | Inhibidor de hdac combinado con un modulador del punto de control inmunitario para la terapia contra el cancer. | |
| DK3240821T3 (da) | Lavdosis gashydrathæmmersammensætning og tilhørende fremgangsmåde | |
| MX2015013021A (es) | 5-bromo-indirrubinas. | |
| PH12016501838A1 (en) | Compounds and their methods of use | |
| GEP20217236B (en) | Composition comprising pentose and polyphenolic compound | |
| MX375355B (es) | Una variante del factor xa para usarse en el tratamiento de la hemorragia cerebral. |